Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
Clinical trial NCT03580382 · TERMINATED
Trial details
- NCT number
- NCT03580382
- Sponsor
- NYU Langone Health
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-06
- Primary completion
- 2018-09-26
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.